Widespread use of nonsteroidal antiinflammatory drugs (NSAIDs)among the elderly has resulted in a large population of personsat risk for ulcer complications. Selective cyclooxygenase-2(COX-2) inhibitors were introduced with the hope that they wouldnot cause gastrointestinal complications. However, it is notclear that this has been the case, and now that the dust hassettled somewhat, it is possible to take a dispassionate lookat the problem.1,2 In this issue of the Journal, Chan et al.3report a randomized comparison of celecoxib and diclofenac plusomeprazole among patients in Hong Kong who had previously hadbleeding from ulcers . . . [Full Text of this Article]
Jacobsen, R. B, Phillips, B. B.
(2004). Reducing Clinically Significant Gastrointestinal Toxicity Associated with Nonsteroidal Antiinflammatory Drugs. The Annals of Pharmacotherapy
38: 1469-1481
[Abstract][Full Text]
Mulshine, J. L., Atkinson, J. C., Greer, R. O., Papadimitrakopoulou, V. A., Van Waes, C., Rudy, S., Martin, J. W., Steinberg, S. M., Liewehr, D. J., Avis, I., Linnoila, R. I., Hewitt, S., Lippman, S. M., Frye, R., Cavanaugh, P. F. Jr.
(2004). Randomized, Double-Blind, Placebo-Controlled Phase IIB Trial of the Cyclooxygenase Inhibitor Ketorolac as an Oral Rinse in Oropharyngeal Leukoplakia. Clin. Cancer Res.
10: 1565-1573
[Abstract][Full Text]
Nurmohamed, M. T., Lems, W. F., Lanas, A., McKeogh, D. F., Chan, F. K.L., Graham, D. Y.
(2003). Celecoxib versus Diclofenac and Omeprazole to Prevent Recurrent Ulcer Bleeding. NEJM
348: 2464-2466
[Full Text]